BOSTON--(BUSINESS WIRE)--The Bioinformatics Infrastructure Congress is the first bioinformatics conference that is solely focussed on tools and unit set-up, rather than application. Join 100+ senior IT, data and informatics professionals looking to modernize research infrastructure for life sciences.
The volume of biological data available to drug companies today requires increasingly sophisticated tools for storage, sharing and analysis. Machine learning, cloud, data commons and quantum computing all offer important discovery prospects for in silico units. But they also present problems such as build vs buy debate, overcoming cultural differences between biologists and data scientists, standardization and interoperability challenges. The Bioinformatics Infrastructure Congress enables IT and computational biology heads from pharma, biotech and academia to explore how to implement new tools and optimize data storage, security, visualization and analysis.
Case studies to be discussed include the Broad Institute’s Dr Anthony Philippakis on how to take best-practice from the tech sector to set up a best-in-class data management centre, the NIH’s Vivien Bonazzi on progress from the NIH Data Commons Pilot Phase and plans for the immediate future as well as MedImmune’s Dr David Fenstermacher on how to integrate data at high volumes so that it is still usable within an organisation.
The congress also features a dedicated Machine Learning Day on Tuesday, May 7th. As drug companies, researchers and health providers update their data management infrastructure the use of Machine Learning tools in life sciences is finally here. The Machine Learning Day takes participants beyond the “what if” and explores how AI and other advanced analytic tools are being used today.
Hear from Dr Ramesh Dursuvala, Vice President and Information Officer, Research Labs on addressing bottlenecks in data collection and standardisation to train ML systems at Eli Lilly; Dr Kelly Zou, Vice President, Head of Medical Analytics and Insights, R&D and Medical, Upjohn Division on changing clinical trial design and execution using algorithms at Pfizer and Mason Victors, Chief Technology Officer on implementing custom data-build to programme an AI for compound discovery and first steps in the clinic at Recursion Pharmaceuticals.
Register to attend before April 5, 2019 to save up to $300 with early bird pricing.
To find out more, visit www.bioinformaticsusa.com
